Related Experiment Videos
Taltirelin (Tanabe Seiyaku).
1Restoragen Inc, 4130 NW 37th Street, Lincoln, NE 68524, USA. BrownWM@aol.com
Idrugs : the Investigational Drugs Journal
|June 3, 2005
Summary
Taltirelin, a synthetic thyrotropin-releasing hormone analog, is the first oral medication approved in Japan for treating spinocerebellar degeneration. Its development marks a significant advancement in neurodegenerative disease therapy.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Development
Background:
- Taltirelin (TA-0910) is a synthetic analog of thyrotropin-releasing hormone (TRH).
- It was developed by Tanabe Seiyaku for treating neurodegenerative diseases.
- Spinocerebellar degeneration (SCD) is a target indication for taltirelin.
Purpose of the Study:
- To report the development and regulatory status of taltirelin.
- To highlight its novel oral administration for SCD.
- To present initial market performance and sales projections.
Main Methods:
- Regulatory filings for New Drug Application (NDA) in Japan.
- Drug launch and post-marketing surveillance.
- Sales data analysis and market forecasting by financial institutions.
Main Results:
- Taltirelin received NDA approval in Japan in July 2000 for SCD. It was launched in September 2000.
- It is the first orally administered drug available for spinocerebellar degeneration.
- Projected sales indicated significant market growth, reaching Yen 7.6-8 bn in 2001 and Yen 8.6-10 bn by 2002-2005.
Conclusions:
- Taltirelin represents a therapeutic breakthrough as an oral treatment for SCD.
- The drug demonstrated strong initial market acceptance and positive sales forecasts.
- Its development underscores advancements in synthetic TRH analogs for neurological disorders.